| Bioactivity | PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model[1]. |
| Sequence | Cys-Lys-Trp-Tyr-Arg-Pro-Ser-Glu-Cys (disulfide bridge: Cys1-Cys9) |
| Shortening | CKWYRPSEC (disulfide bridge: Cys1-Cys9) |
| Formula | C51H72N14O14S2 |
| Molar Mass | 1169.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhai W, et al., Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy. Sci China Life Sci. 2021 Apr;64(4):548-562. |
PD-1/PD-L1 inhibitory peptide C8
CAS: F: C51H72N14O14S2 W: 1169.33
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.